BEDMINSTER, N.J., Jan. 30 /CNW/ -- NPS Pharmaceuticals, Inc. (Nasdaq:
NPSP) announced today that its board of directors has elected Peter Tombros
chairman of the board and appointed Francois Nader, M.D. as a director. Mr.
Tombros joined the NPS board in 1998 and has served as lead director since
2006. Dr. Nader joined NPS in 2006 as chief medical and commercial officer
and currently serves as executive vice president and chief operating officer.
Dr. Nader's appointment increases the number of board members to eight.
Mr. Tombros stated: "I am pleased to be leading the NPS board at this
important point in the company's history and look forward to working with the
board and senior management to advance the NPS product portfolio. With the
completion of the company's restructuring last year, NPS is now in a much
stronger financial position to execute successfully its clinical development
plans for GATTEX and PREOS."
Tony Coles, M.D., president and chief executive officer of NPS, stated:
"I congratulate Peter on his appointment as chairman and look forward to his
continued leadership of the NPS board. I also congratulate Francois on his
appointment to the NPS board. Francois has brought strong management,
strategic and clinical experience to NPS and his contributions as a director
will be invaluable as we work to develop and gain approval for our most
important assets, GATTEX and PREOS."
Mr. Tombros is currently professor and executive in residence in the
Eberly College of Science B.S. / M.B.A. Program at Pennsylvania State
University. Prior to that, he was chairman of the board and chief executive
officer of VivoQuest, a private biopharmaceutical company. From 1994 until
June 2001, Mr. Tombros served as president, chief executive officer and
director of Enzon Pharmaceuticals, Inc., a publicly held biopharmaceutical
company. Prior to joining Enzon, Mr. Tombros spent 25 years with Pfizer Inc.,
a global healthcare company, in a variety of senior management positions
including: vice president of marketing; senior vice president, and general
manager of the Roerig Pharmaceuticals Division; executive vice president and
director of Pfizer Pharmaceuticals Division; vice president of corporate
strategic planning; and vice president, corporate officer of Pfizer Inc. In
addition to NPS, Mr. Tombros serves on the boards of directors of Alpharma
Inc., Cambrex, PharmaNet Development Group, Inc. and Protalex, Inc.
Dr. Nader is responsible for managing the company's worldwide R&D,
Commercial Operations, Manufacturing and Regulatory Affairs. Previously, he
was a venture partner at Care Capital, LLC and chief medical officer of its
Clinical Development Capital unit. Prior experience includes senior vice
president, integrated healthcare markets and North America medical and
regulatory affairs with Aventis Pharmaceuticals as well as similar positions
at Hoechst Marion Roussel and its predecessor companies. Before joining
Hoechst Marion Roussel, Dr. Nader served as head of global commercial
operations at the Pasteur Vaccines division of Rhone-Poulenc.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company focused on the
development and commercialization of small molecules and recombinant proteins
as drugs, primarily for the treatment of metabolic, bone and mineral, and
central nervous system disorders. The Company has drug candidates in various
stages of clinical development. Additional information is available on the NPS
Statements made in this press release, which are not historical in
nature, constitute forward-looking statements for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995. These
statements are based on the company's current expectations and beliefs and are
subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements. Risks associated to NPS's business include, but are not limited
to, the risk of successfully executing its clinical development plans and
gaining marketing approvals for GATTEX and PREOS, as well as other risks that
are described in NPS's periodic filings with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 10-K for the year ending
December 31, 2007 and its Form 10-Q for the quarter ended September 30, 2007.
All information in this press release is as of the date of this release and
NPS undertakes no duty to update this information.
For further information:
For further information: Susan Mesco of NPS Pharmaceuticals, Inc.,
+1-908-450-5516 Web Site: http://www.npsp.com